Wall Street analysts forecast that Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will announce $3.14 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Adaptimmune Therapeutics PLC’s earnings. The highest sales estimate is $3.50 million and the lowest is $2.92 million. Adaptimmune Therapeutics PLC posted sales of $2.42 million during the same quarter last year, which suggests a positive year-over-year growth rate of 29.8%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Adaptimmune Therapeutics PLC will report full-year sales of $3.14 million for the current fiscal year, with estimates ranging from $12.21 million to $15.00 million. For the next financial year, analysts anticipate that the company will report sales of $17.42 million per share, with estimates ranging from $11.67 million to $30.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.24). The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%.

A number of equities research analysts recently commented on the stock. SunTrust Banks, Inc. reissued a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics PLC in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Wednesday, October 4th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Leerink Swann restated an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics PLC currently has an average rating of “Hold” and a consensus price target of $11.58.

Several hedge funds have recently modified their holdings of the company. Alps Advisors Inc. raised its stake in shares of Adaptimmune Therapeutics PLC by 4.9% in the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 2,996 shares in the last quarter. Matrix Capital Management Company LP bought a new stake in shares of Adaptimmune Therapeutics PLC during the second quarter worth $39,027,000. Point72 Asset Management L.P. bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $2,883,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $120,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Adaptimmune Therapeutics PLC by 75.4% during the first quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after purchasing an additional 335,700 shares during the last quarter. Institutional investors own 68.01% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “$3.14 Million in Sales Expected for Adaptimmune Therapeutics PLC (ADAP) This Quarter” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/18/3-14-million-in-sales-expected-for-adaptimmune-therapeutics-plc-adap-this-quarter.html.

Shares of Adaptimmune Therapeutics PLC (NASDAQ ADAP) opened at 7.01 on Wednesday. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $9.29.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.